Analysis of biomarkers and subgroups to determine their correlation with clinical efficacy
tumor
TUMOR
Patients exhibiting PD-L1-positive expression (with a TPS ≥ 1%) derived greater benefits from sintilimab treatment compared to individuals with PD-L1-negative status (with a TPS < 1%), although the difference was statistically insignificant (66.7% ORR versus 33.3% ORR, Evaluating the relationship between clinical efficacy and PD-L1 expression as determined by IHC staining in tumor biopsies. Subdivisions of PD-L1 expression by anti-PD-L1 antibody (DACO, 22C3) IHC staining to determine their correlation with objective response (